Sara Pilotto
Sara Pilotto is an expert in Oncology at Azienda Ospedaliera Universitaria Integrata Verona (Italy). As of October 2026, ScienceLeadR ranks Sara Pilotto in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Sara Pilotto has authored 379 publications, the most recent in 2026, and is an investigator in 24 clinical trials, 13 of them ongoing. SLR score: 1,770 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Immunology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 379
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study. PMID 42697029 — cells, lung, disease-free survival, progression-free survival, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy | Clin Lung Cancer | 2026 | 0 |
| Correction: HLA-G expression in non-small cell lung cancer: prognostic significance and interplay with PD-L1 and CD8+ tumor-infiltrating lymphocytes. PMID 42516371 — cells, hla-g antigens, lung, lymphocytes, lymphocytes, tumor-infiltrating, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, immune system diseases, small cell lung carcinoma, immune evasion | Front Immunol | 2026 | 1 |
| HLA-G expression in non-small cell lung cancer: prognostic significance and interplay with PD-L1 and CD8 + tumor-infiltrating lymphocytes. PMID 42367769 — cells, hla-g antigens, lung, major histocompatibility complex, lymphocytes, lymphocytes, tumor-infiltrating, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, immune system diseases, small cell lung carcinoma, immune evasion | Front Immunol | 2026 | 1 |
| Physical activity level and its determinants in patients with cancer: a secondary analysis using a decision-tree approach. PMID 42260253 — exercise, neoplasms, neoplasms by site | J Cancer Surviv | 2026 | 0 |
| Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry. PMID 42216441 — registries, cells, epidermal growth factor, lung, growth, safety, neoplasms, carcinoma, non-small-cell lung, exanthema, exons, lung neoplasms, receptors, growth factor, small cell lung carcinoma, therapeutics, mutation | Cancer | 2026 | 0 |
Clinical Studies 24
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
13 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment 2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation | Phase 3 | Not yet recruiting | 2026 |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First line Treatment of PD L1 high Metastatic Non small Cell Lung Cancer 2024-517780-24-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics | Phase 3 | Recruiting | 2025 |
| A Study to Learn About the Study Medicine Called PF 08046054 SGNPDL1V Versus Docetaxel in Adult Participants with Previously treated Programmed Cell Death Ligand 1 (PD L1) Positive Non small cell Lung Cancer (NSCLC) 2025-521281-97-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, ligands, cell death | Phase 3 | Recruiting | 2025 |
| A clinical study of V940 and pembrolizumab to treat lung cancer (V940 009) 2023-506327-29-00 — cells, lung, polymerase chain reaction, neoplasms, carcinoma, non-small-cell lung, double-blind method, drug therapy, lung neoplasms, small cell lung carcinoma, chemotherapy | Phase 3 | Recruiting | 2025 |
| A clinical study of MK 1084 and other treatments for lung cancer (MK 1084 007) 2024-514500-14-00 — pemetrexed, lung, safety, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, therapeutics, carboplatin, chemotherapy | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map